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HYPOTHESIS
Stem cell origins of leukaemia and curability
M.F. Greaves
Leukaemia Research Fund Centre, Institute ofCancer Research, Chester Beatty Laboratories, 237 Fulham Road, London
SW3 6JB, UK.
Summary It is suggested that most childhood acute lymphoblastic leukaemias and some other paediatric
cancers are chemo-curable because they arise in stem cell populations that are functionally transient, chemo-
sensitive and programmed for apoptosis. Most adult acute leukaemias are chemo-incurable at least in part
because they originate in relatively drug resistant stem cells with extensive self-renewal capacity. The latter
property in turn increases the probability of clones evolving with multi-drug resistance. Particular mutations
may superimpose additional adverse features on leukaemic cells.
Curability of childhood leukaemia
Childhood acute lymphoblastic leukaemia (ALL) has pro-
vided a landmark in cancer therapy as the first disseminated
and otherwise lethal malignancy to be curable in the majority
of patients. This success originated over a 30 year period,
despite a tide of deep pessimism, with the introduction by
Farber et al. (1956) of single agent drugs to induce tem-
porary remissions followed by the elaboration of combina-
tion chemotherapy for both induction and maintenance of
remission, the addition of prophylactic CNS radiation to
cope with the major extramedullary sanctuary and the
intensification of treatment for higher risk patients. This
accumulative progress over 40 years now provides an expec-
tation of very long term remission and probable cure in
approximately 75% of children with ALL who have access to
the best treatment (Pinkel, 1979; Simone, 1979a; Gale &
Hoelzer, 1990; Riehm, 1991).
The hope that this pattern of progress and the strategies
used could be built upon to improve treatment and outcome
in other cancers has met with only partial and very selective
success. Thus whilst several of the paediatric cancers includ-
ing, in particular, Hodgkin's disease and Wilms' tumour now
have very high cure rates of around 90% (Pochedly, 1987;
Crist & Kun, 1991), amongst adult disseminated or meta-
static cancers the story remains dismal, testicular teratoma
providing one of the few examples of effective treatment
(Einhorn, 1990). In marked contrast also to leukaemia in
childhood, acute leukaemias in adults have proven much
more intransigent to combination chemotherapy; the best
estimates of cure rates for adult (> 15 years) ALL and acute
myeloid leukaemia (AML) are around 30% (Gale & Hoelzer,
1990; Gale, 1990). Some optimism still remains that this
picture will improve with newer or more intensive regimes of
induction chemotherapy for adult leukaemias, but it is clear
that a striking difference in clinical response to chemotherapy
exist between these different cancers in association with age,
cancer type or both.
Several factors could collectively account for this pattern
of selective curability. First, it could be argued that the very
systematic collaborative and multi-disciplinary approach to
the development and application of multi-agent chemothera-
peutic strategies and supportive care for childhood cancers
has not really been taken on board for most adult cancers.
This seems very unlikely to be the explanation. Second,
children may be diagnosed and receive systemic therapy at a
relatively early stage in disease progression. Third, children
may have much better vital tissue regenerative capacity than
adults enabling them to withstand and recover from toxic
side-effects of intensive treatment. The latter is almost cer-
tainly a relevant factor with respect to the substantial frac-
tion of patients over 60 years of age with leukaemia or
cancer. This is unlikely to be the whole explanation, however,
since some childhood cancers remain difficult to treat success-
fully (e.g. metastatic neuroblastoma; infant leukaemia) and
some adults are successfully cured.
Physicians who have played prominent roles in the treat-
ment of childhood leukaemia have suggested possible ex-
planations for the effectiveness of chemotherapy for paediat-
ric ALL. Simone has suggested that the disease (or leukaemic
cell population involved) is in some way intrinsically sensitive
to chemotherapy as evidenced by dramatic responses to
different drugs given as single agents (Simone, 1979b). Opera-
tionally speaking, Simone must be correct but this does not
provide us with a biological explanation. A somewhat
different view is held by Pinkel (1987). He suggests that the
genetic alterations underlying leukaemic cell transformation
disrupt cell phenotype to an extent that a clear relationship
to normal cells cannot be ascertained. Efficacy of treatment,
he suggests, somehow relates to the ability of the drugs used
to induce clinical remissioon by killing the bulk of tumour but
cure of the disease is achieved by drugs used in maintenance
of remission (e.g. methotrexate) that are capable of neutraliz-
ing or reversing the abnormal genetic programme in remain-
ing leukaemic cells allowing them to respond to normal
physiological signals promoting differentiation. It follows
from this, Pinkel argues, that therapy should be dictated by,
and targeted to, the genotype of the leukaemia (rather than
presumed cell type) and cites as evidence the correlation
between clinical outcome and presence of particular chromo-
some translocations and/or oncogene alterations.
It is self-evident that genetic alterations in cancer will
indeed modify cell phenotype, differentiation competence,
growth rates, probability of subsequent mutations, and con-
comitantly influence susceptibility of the leukaemic cell
population to drugs. In this article, I am proposing that these
effects, though important, are superimposed upon more
fundamental mechanisms that provide the primary deter-
minant of curability. The explanation suggested here, as a
hypothesis, runs contrary to Pinkel's views only in so far as
properties of the cell type in which cancer originates are
considered to be of importance with respect to subsequent
clinical response and that curable and incurable leukaemias
may on the whole, though not exclusively, originate in
different cell types. The theory is relevant also to a considera-
tion of other 'curable' paediatric cancers. Adult cancers other
than leukaemias are not considered except to point out that
the unusual curability of one of them may owe its success to
certain features shared with lymphoid progenitor cells (see
Addendum).
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When is a stem cell a stem cell?
Stem cells are usually considered as long-lived and, perhaps,
immortal cells that normally reside out of cycle, in Go, but
can be induced to proliferate and either self-renew (i.e. pro-
duce another stem cell) over many repeat cycles (>200)
(Lajtha, 1979; Potten & Loeffler, 1990) or produce
differentiating progeny of one or more lineages. The alterna-
tive pathways are balanced overall to maintain steady state
conditions. The only unequivocal examples of normal stem
cells defined by these criteria are in tissues that self-renew
throughout life, i.e. stratified squamous epithelia, male germ
cells in the testes and the haemopoietic system (Lajtha, 1979;
Hall & Watt, 1989; Potten & Loeffler, 1990). Many haemo-
poietic lineage diagrams show multi-potential stem cells giv-
ing rise to transitory lineage committed progenitor cells
which themselves proliferate to produce maturing descendent
cells but which, unlike stem cells, do not self-renew. In other
words, self-renewal and differentiation are considered to be
strictly compartmentalised and mutually exclusive. As others
have argued (Potten & Loeffler, 1990), this rigid model is
almost certainly incorrect. A more plausible scheme allows
for stem cells to be a heterogeneous population and for
self-renewal and differentiation to be inversely related in a
progressive hierarchical manner rather than all or none and
for the balance between these two properties to be regulated
or determined by micro-environmental signals. Circumstances
when otherwise transitory progenitors might self-renew and
therefore express stem cell-like characteristics would include
particular culture conditions in vitro (Spooncer et al., 1986),
during phases of regeneration in vivo, e.g. following recovery
from toxic chemotherapy, radiation and/or transplantation
(Potten & Loeffler, 1990) and during ontogeny (see below).
Under these circumstances, however, self-renewal will be time
limited. The existence of these temporary periods of stem
cell-like behaviour are significant because they could denote
periods during which these proliferating cell populations are
at extra risk of mutation.
The sites of B and T lymphopoiesis (foetal liver/bone
marrow and thymus respectively) are invaded, during
ontogeny, by a few, time-limited waves of proliferating,
stroma-dependent progenitor cells (Le Douarin, 1978;
Strasser et al., 1989). This developmental 'window' provides
the opportunity required for clonal diversification of Ig/T cell
receptor genes (Alt et al., 1986) before further differentiation
and clonal selection occurs. Although B cell production con-
tinues throughout life, proliferation in the precursor com-
partment is much more extensive in very young animals
(Miller & Osmond, 1975). In the T cell system, the thymus
atrophies in the post-pubertal period (Clarke & MacLennan,
1986) and fewer T cells are presumably processed thereafter.
Note that mature lymphoid cells are unique since as
differentiated cells, they can express some stem cell properties
including, in the case of T cells, life-spans (in interphase/Go)
of decades, extensive self-renewal and proliferative capacities.
It is probably for this reason that lymphocytes alone
amongst mature or fully differentiated cells are vulnerable to
malignant transformation.
Lymphopoiesis is also characterised by very extensive
apoptosis, an active process involving protein synthesis,
endonuclease activation and DNA fragmentation (Wyllie,
1981). Moreover, most lymphocytes are very sensitive to
DNA-damaging agents, a feature they share with few other
cell types tested, with the interesting and relevant exception
of male germ cells. For example, mature lymphocytes are
very unusual in being susceptible to interphase death with
ionising (y, X)-radiation (Maruyama & Feola, 1987) and are
very sensitive to steroid-induced apoptosis (Wyllie, 1981).
Lymphocyte progenitor populations may be ultra-sensitive to
DNA damage. The extreme sensitivity of cortical thymocytes
(T cell precursors) to steroids and 'y-radiation has been recog-
nised for decades (Trowell, 1952), the lethal effects in both
cases appearing to follow the apoptotic pathway (Sellins &
Cohen, 1987). Recent observations indicate that clonogenic B
cell progenitors have a unique sensitivity to ionising radiation
equalling or surpassing that of cells that are mutants for
DNA repair (Griffiths et al., in preparation). These cells are
killed by a single passage of a-particles (plutonium-238) and
have a Do for x-rays of -0.3 Gy. The basis of this intrinsic
vulnerability of lymphoid cells may include the accessibility
of the apoptosis programme (Wyllie, 1981; Griffiths et al., in
preparation) and a reduced ability to repair double stranded
DNA breaks (Mayer et al., 1986). In these respects lymphoid
progenitors are considerably more susceptible than myeloid
progenitors or multi-potential haemopietic stem cells (Gold-
schneider et al., 1979; Griffiths et al., in preparation); indeed,
a substantial fraction of the latter are remarkably resistant to
a wide range of drugs. Several mechanisms could contribute
to stem cell resistance, including effective DNA repair
capacity, residence out of cycle with concomitant loss of
dependence on growth factors or vulnerability to apoptosis
(Leary et al., 1989), and high level expression of gene prod-
ucts associated with drug resistance including the multi-drug
efflux pump P glycoprotein (Chaudhary & Roninson, 1991)
and aldehyde dehydrogenase (Kastan et al., 1990).
Stem cells have been regarded as the principal or exclusive
'target' cell population for the initiation of malignancy since
their longevity provides the requisite opportunity for subse-
quent independent mutations within the same clone whilst
accommodating the principles of latency and differentiation
arrest (Cairns, 1975; Buick, 1987; Pierce & Speers, 1988;
Potten & Loeffler, 1990). Transit cells, by the same criteria,
have been considered poor or ineffective targets. Clearly,
these boundaries of vulnerability change when a less struc-
tured definition of stem-ness is allowed, especially for tissues
such as the lymphoid system.
With respect to malignancy in the haemophoietic system,
therefore, cells at three development stages (Figure 1) are
potentially at risk ofmutation and clonal selection leading to
leukaemia or other blood cell malignancies (lymphoma,
myeloma). Rarely, cells ancestral to the haemopoietic system
including embryonic germ cells (Nichols et al., 1990) or the
parental germline (Felix et al., 1992) may also provide targets
for initiating mutations that lead to leukaemia.
An hypothesis
Extensive studies on radiation treatment and chemotherapy,
both in animal model systems and in human cancer have
suggested that one key factor in determining curability or
resistance is likely to be the total burden of clonogenic or
stem cells in the tumour, these cells being responsible for
sustaining tumour growth and hence the relevant target
population for therapy (Skipper & Schabel, 1984; Trott,
1984; McGuire et al., 1985, Buick, 1987). In acute leukaemia,
this association is reflected in the correlation between in vitro
clonogenicity and adverse prognosis (McCulloch et al., 1982).
It follows from this that the intrinsic stem cell properties of
the 'target' cells for different types of leukaemia or cancer
might be expected to have an impact on curability. Based on
these considerations, an hypothesis to explain the marked
difference in curability between acute leukaemia in children
and adults is as follows.
(1) The major 'target' cells for leukaemia in children are B
lymphoid (and to a lesser extent T and myeloid) com-
mitted progenitor cells (Greaves, 1986). During a
limited period of early development, these cells have
extensive self-renewal capacity regulated by specialised
stromal/growth factor conditions in foetal liver and,
subsequently, bone marrow (Kincade, 1987; Rolink &
Melchers, 1991) but they differ from true stem cells by
their finite self-renewal capacity and their low pro-
bability of an exit from cycling, i.e. they are still tran-
sitory cells. These same cells are programmed for cell
death (apoptosis) and can only be rescued by finding
the correct developmental niche (stroma/growth fac-
tors) that facilitates proliferation and/or differentiation
(plus they must achieve functional Ig/TCR gene rear-
rangement) (Hardy et al., 1991a). Leukaemic transfor-LEUKAEMIC STEM CELLS 415
Lineage
restricted
progenitors
+++ _0 _
age
Precursor
cells
I t
Predominant in
44 adults
t L Lymphoma _
CLL
IMyeloma
Figure 1 Development associations of leukaemia and stem cells.
t, cell death. S, DNA synthesis, cell proliferation. Go, non-cycling cells. L = lymphoid. M = myeloid. + ++ = extensive self-
renewal capacity; + ++ -* - (age) = variable self-renewal capacity (associated with age) from extensive (+ + +) to zero (-).
mation of these cells may be facilitated by the intrinsic
mutagenicity of the recombinases (Fuscoe et al., 1991)
and TdT (Kunkel et al., 1986) that are involved in
immunoglobulin gene diversification (Lieber, 1992;
Schatz et al., 1992). The leukaemic (B precursor) pro-
geny of the clonogenic cells in acute lymphoblastic
leukaemia (ALL) inherit ultra-sensitivity to apoptosis-
inducing drugs or ionising radiation. The crucial corol-
lary is that in most cases, the leukaemogenic mutations
are not in genes that, when dysregulated, can block
apoptosis. The clonogenic cells, though potentially
immortal, are a very minor fraction of the total
leukaemic cell population but, initially at least, they
too are also very sensitive to the lethal effects of drugs
and ionising radiation. Killing of the great majority, or
all, of these leukaemic cells and potential cure is
therefore possible provided therapy is adequately
delivered prior to the emergence of subclones that are
mutants for drug uptake or apoptosis. A minority of
patients presenting with a common ALL phenotype
but with a very high white cell count at diagnosis are
likely to be at a significant disadvantage in this respect.
Normal B cell progenitors will also be obliterated but
the potentially hazardous sequelae of such a loss will
be avoided as this cell population is replenished from
the largely intact and relatively drug resistant pool of
lympho-myeloid stem cells.*
(2) The majority of adult acute leukaemias (ALL, AML
*This interpretation supposes that cure is due to elimination of
effectively all clonogenic ALL cells. Recent studies in which residual
disease in long term remission is assayed by PCR for clone specific
IgH rearrangements are compatible with this view (Yamada et al.,
1990; Yokota et al., 1991). It is, however, striking in these studies
that leukaemic cells persisted for up to 18 months in patients who
remain in long term remission.
and acute phase CML) and a minority of childhood
leukaemias, originate in more primitive multi-potential
stem cells. These are major targets in adults because
the extended time scale involved (decades) provides the
opportunity for accumulation of two or more muta-
tions in cells that divide infrequently. The clonogenic
cell population in these leukaemias, in contrast to
childhood ALL, are resistant to complete ablation by
chemotherapy because (i) their inherently greater self-
renewing capacity, constitutively expressed following
transformation, results in a larger total burden of
clonogenic cells. They can only be completely elimin-
ated by killing or damaging normal haemopoietic cell
stem cell populations below the level of tolerance; (ii)
they may be inherently less sensitive as individual cells
to DNA damaging agents then clonogenic lymphoid
progenitors (see above). Progeny of these clonogenic
leukaemic stem cells may nevertheless express the more
susceptible phenotype of differentiated progenitor/
precursor populations; clinical, but not biological,
remission can therefore be achieved, and. (iii) the
larger total burden of accumulated stem cells substan-
tially increases the likelihood that drug resistant
mutants will exist by the time that treatment is
initiated (see Table I).
Two important caveats are as follows:
(1) Butturini and Gale argue (1989a) that the age depen-
dent pattern of leukaemic subtypes is a feature of
exposure to particular aetiological agents or pathways
rather than a reflection of intrinsic changes in cell
populations with age. The above hypothesis is not
defined in terms of aetiological agents but is certainly
compatible with an interactive model in which both
cell population characteristics and exposure to
hypothetical aetiological factors may be rate limiting
and time constrained. For example, the common (and
curable) variant of childhood ALL has been suggested416 M.F. GREAVES
Table 1 Characteristics of haemopoietic cells that may influence leukaemogenesis and treatment outcome
Features that influence vulnerability Features that influence chemo-
to leukaemogenesis ( + or -) curability of leukaemias ( + or -) Malignancies
I Multi-potential Majority out of cycle (-) Intrinsically chemo-resistant, plus CML
stem cells Smaller number (-) acquired resistance through extensive Most adult AML, ALL
Extensive self-renewal capacity self-renewal (-)
(and longevity as clone) Proportionally high content of
(+ over long time-frame) clonogenic cells (-)
Irreplaceable (-)
2 Lineage-restricted Majority in cycle, Chemo-sensitive. +) Most childhood acute
progenitor cells large numbers during developmentally Proportionally low content of leukaemias
timed periods, clonogenic cells (+)
finite self-renewal (developmentally Replaceable ( +)
timed) ( +, in early development,
decreasing risk with time)
3 Mature cells:
Myeloid Dying end cells (-) None
Lymphoid Majority out of cycle (-) but Chemo-sensitive (+) but Chronic lymphoid
periodically activated by acquired resistance through leukaemias
antigen ( + ) extensive self-renewal ( Non-Hodgkin's
Large numbers ( +) Replaceable ( +) lymphoma
Extensive self-renewal capacity ( +) Myeloma
aOr resistance induced by BCL-2 rearrangements (see Appendix).
to arise in part as a result of altered patterns of
infection in infancy (Greaves, 1988). Recent epidemio-
logical evidence provides some persuasive, if indirect,
support for this view (Alexander et al., 1990; Kinlen et
al., 1990; Draper et al., 1991; reviewed in Greaves &
Alexander, 1992).
(2) Even within what appears to be an intrinsically curable
cancer such as childhood ALL, prognostic variables
have been identified in the past including total white
cell count and other indicators of 'tumour' load but
also cell type and karotypic markers. High white cell
count is a highly significant and independent indicator
of poor prognosis. A minority of patients with B cell
precursor (common) ALL present with high counts, as
do a more substantial proportion of the less common
T-ALL. These patients usually obtain remission but
frequently relapse, indicating perhaps that a high
tumour burden is likely to be associated with a larger
pool size of clonogenic cells and hence a higher pro-
bability of drug resistant mutants. Common ALL with
hyperdiploidy usually presents with modest white cell
counts and require less intensive treatment in order to
induce and sustain long term remissions than cytoplas-
mic p chain positive B precursor subset of common
ALL or those with T cell phenotypes (Pui et al., 1990).
With more effective treatment schedules, some of these
prognostic correlates may lose significance (Pui et al.,
1990). This variability could be dependent upon intrin-
sic features of the particular cell type involved or varia-
tion in the timing of diagnosis in relation to the
natural history of the disease. It may also, in some
cases at least, reflect the super-imposition of adverse
leukaemic features per se as argued by Pinkel. The
Philadelphia chromosome positive leukaemias are
especially interesting in this regard.
Clonogenic origin, cellular phenotype and curability: lessons
from Ph-positive leukaemias
The hypothesis proposed here had its historical origins in a
consideration of the remarkable difference in curability of
two leukaemias that appeared to involve the same cell type
(Greaves, 1982); these are the common (c) variant of acute
lymphoblastic leukaemia and lymphoid blast crisis of CML.
The leukaemic cells in each leukaemia have a B lineage
precursor phenotype with clonal rearrangements of IgH
genes (Greaves et al., 1979; Bakhshi et al., 1983; Ford et al.,
1983; Greaves, 1986). Common ALL represents the high cure
rate subgroup of ALL in children (Chessells et al., 1977;
Sallan et al., 1980; Greaves et al., 1981). On the basis of the
equivalent morphology and immunophenotype, patients with
lymphoid blast crisis of CML were treated with chemothera-
peutic regimes appropriate for ALL (Marks et al., 1978;
Janossy et al., 1979). Remission was achieved in a majority
of patients; these were, however, relatively short-lived and
few, if any, patients with lymphoid or myeloid blast crisis of
CML survive for more than 2 years (Shaw, 1982). Since it
was already known by that time (by lineage analysis ofclonal
markers) that CML was a lympho-myeloid stem cell disease
(Fialkow, 1980), the explanation offered for the marked
difference in curability was that illustrated in Figure 2. This
model predicts that comparable lymphoid precursor pheno-
types of the 'bulk' leukaemia cell population will be paralled
by remission induction but that the critical difference in cure
in the two leukaemias resides in distinct clonogenic stem cell
origins.
The evidence that most cALL in children does, as predict-
ed, originate in B lymphoid progenitor cells rather than
multi-potential stem cells, rests on the observation that
myeloid cells in such patients are not demonstrably part of
the leukaemic clone as indicated by the use of X-linked
polymorphisms as markers - glucose 6-phosphodehydro-
genase (Dow et al., 1985), HPRT and PGK (Greaves et al.,
1991; Ford, Pegram and Greaves; unpublished data). More
conclusive evidence could be obtained now from analysis of
individual myeloid cells or colonies by combined genotype
(FISH)/immunophenotype methods (Price et al., 1992) or by
PCR (Hernandez et al., 1990). It will be important to apply
these methods also to the subset of adult ALL that are
curable and therefore predicted to be lymphoid restricted in
origin.
These data are in accord with the restricted stem cell
hypothesis for curable childhood leukaemia but suffer from
the fact that they do not accommodate the 'Pinkel' inter-
pretation, i.e. since CML in lymphoid blast crisis have a
BCR/ABL (p210) rearrangement (plus other genetic altera-
tions), which most childhood ALL do not have, how can we
rule out that it is this acquired molecular feature which
determines the incurability of CML in lymphoid blast crisis?
This point becomes even more significant and interesting
when ALL presenting with the Ph chromosome (i.e. no
preceding chronic phase or CML) are considered (Beard et
al., 1976; Peterson et al., 1976). These cases usually have a B
cell precursor immunophenotype (Janossy et al., 1978)
equivalent to that of Ph-negative cALL, although some have
mixed lineage or 'Iympho-myeloid' characteristics (Hirsch-
Ginsberg et al., 1988). Ph-positive ALL have an extremely
poor prognosis (Bloomfield et al., 1986; Ribeiro et al., 1987;
Pui et al., 1990); few, if any, are curable by chemotherapy. InLEUKAEMIC STEM CELLS 417
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Figure 2 Relationship between clonogenic 'target' cells and chemotherapeutic cure in ALL versus ALL-like lymphoid blast crisis
of CML. c = cell death induced by chemotherapy. d = differentiation arrest. 1', 2', sequential genetic events (in CML). X, genetic
event(s) giving rise to common ALL (Ph-). Lymphoid blast crisis of CML could, in theory, arise by mutations in either a
(Ph-positive) committed lymphoid stem cell/progenitor cell, or (as shown in Figure 2) a (Ph-positive) lympho-myeloid stem cell
whose progeny then preferentially and partially differentiate into early (B) lymphoid cells. Either way, transient haematological
remission might be expected because of the intrinsic sensitivity of these progeny cells but this will not be sustained because of the
existence of residual clonogenic cells in the more primitive lympho-myeloid stem cell compartment that are capable of resurrecting
the blast crisis status.
a study from St Jude Hospital, there were only two out of 18
long term survivors of children with Ph-positive ALL; those
two had variant translocations involving 22ql1 (Ribeiro et
al., 1987). Subsequent studies have revealed that these variant
forms may not involve detectable BCR/ABL kinase (Dow et
al., 1989) and are, therefore, distinct from classical Ph-
positive leukaemias. The presence of the Ph chromosome
appears to be prognostically significant, independent of other
clinical parameters including white cell count (Secker-Walker
et al., 1991). Significantly, far more adult (-"'25%) than
children (-3.5%) with ALL are Ph-positive (Bloomfield et
al., 1986; Ribeiro et al., 1987; Pui et al., 1990). The children
with Ph-positive ALL are older than average (Ribeiro et al.,
1987). Recent studies indicate that the proportion of adult
ALL that are Ph-positive also increases with age (Maurer et
al., 1991; Secker-Walker et al., 1991). Age is itself a
significant prognostic variable in ALL (Henderson et al.,
1990). Collectively, therefore, these data suggest that a major
factor contributing to the substantial age-linked variation in
chemo-curability of ALL is the incidence of Ph-positive
disease (Figure 3).
If we accept that the common form of (Ph-negative) ALL
in children might indeed be curable for the reasons suggested
above, then the issue for chemo-incurability of Ph-positive
ALL (and perhaps adult acute leukaemia in general) is
whether this reflects a multi-potential stem cell origin, and
therefore 'intrinsic' resistance or whether the BCR/ABL
kinase (and other chromosomal/molecular abnormalities
commonly found in Ph-positive ALL; Rieder et al., 1991;
Russo et al., 1991) enables the leukaemic cell to over-ride
intrinsic susceptibility (the Pinkel argument). The cellular
origins of Ph-positive ALL are clearly germane to this issue.
Could this be a lympho-myeloid stem cell leukaemia despite
its predominant B cell precursor phenotype? When Ph-
positive ALL was first described (Beard et al., 1976), it was
suggested that these were in fact lymphoid blast crises evolv-
ing from clinically covert CML. That some patients reverted,
following treatment, to a CML-like picture (Catovsky, 1979)
lent strong support for this view. Attempts to determine the
origin of Ph-positive ALL more directly by clonal analysis
has, however, produced somewhat conflicting results.
Analysis of myeloid cell populations or colony-forming
cells in some cases of Ph-positive ALL has indicated that
they lack detectable Ph chromosome or BCR/ABL rear-
rangements (Kitano et al., 1988; Craig et al., 1990). These
observations are open to several interpretations but taken at
face value do not support a lympho-myeloid stem cell origin
for Ph-positive ALL. In other cases of Ph-positive ALL,
however, the Ph chromosome or its molecular lesion have
been detected in myeloid cells providing formal proof of a
multi-potential stem cell origin (Tachibana et al., 1987; Tur-
han et al., 1988; reviewed in Secker-Walker & Craig, 1993).
At present, therefore, it seems likely that the relatively high
frequency of Ph-positive ALL in adults contributes very
significantly to the chemo-incurability of most adult patients
but that the two alternative explanations discussed above do
not enjoy exclusive support. Possibly therefore a multi-
potential stem cell origin and the presence of the BCR/ABL
kinase can both contribute significantly to the intransigence
of Ph-positive adult ALL to chemotherapy.
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Figure 3 Frequency of Ph-positive ALL with age. Data derived from references 75 and 78.
Similar arguments apply to childhood versus adult AML
although here the Ph chromosome plays only a very minor
role. In AML, there is evidence, again from analysis of
clonality by X-linked polymorphisms, that the largely intract-
able disease in older adults may predominantly originate in a
primitive multi-potential stem cell (Fialkow et al., 1987).
Additionally, several forms of clonal haemopoietic dysplasias
in adults with a high probability of progressing to AML
involve a common lympho-myeloid stem cell (Fialkow, 1984;
Buschle et al., 1988). AML in children requires more inten-
sive chemotherapy than ALL and has an appreciably lower
complete remission rate, remission duration and cure rate
than childhood ALL (Kalwinsky et al., 1988; Gale, 1990).
However, long term remissions and possible cures are now
obtainable in a substantial fraction (30-50%, cf 15-20% in
adults) (Clarkson et al., 1990; Rohatiner & Lister, 1990;
Schellong et al., 1990). In children and younger adults, the
disease appears to be more frequently (though not exclus-
ively) clonally restricted to a single (granulocytic) lineage
indicating a possible origin from a more differentiated
myeloid progenitor cell (Fialkow et al., 1987) which may
nevertheless be intrinsically less drug sensitive than their
lymphoid counterparts. Interestingly, as in adult ALL,
inferior prognosis in adult AML is very significantly cor-
related with increasing age (Gehan et al., 1976; Rohatiner et
al., 1990). This still holds true if very old patients are ex-
cluded. These observations are compatible with the view that
paediatric AML arising in myeloid committed progenitor
cells are more drug sensitive than those arising in more
primitive lympho-myeloid stem cells, but are nevertheless less
sensitive to eradication than paediatric ALL cells because
they do not share the critical attributes identified in lymphoid
progenitor cells. Direct evidence for this view comes from
recent studies comparing the sensitivity of clonogenic B cell
precursor versus myeloid cells to ionising radiation and
apoptosis-inducing drugs dexamethasone, cisplatinum and
etoposide (Griffiths et al., in preparation).
Collectively then, these observations are largely compatible
with the model proposed. However, at present, the evidence
is incomplete and alternative explanations cannot be entirely
ruled out.
Age related cancer incidence rates and stem cell origins
Figure 4 illustrates a comparison of age related incidence
rates of three different malignancies. Aside from the enor-
mous numerical differences in incidence rates, the striking
feature is the shape of the incidence rate curves which are
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Figure 4 Age related cancer incidence rates.
ALL, osteosarcoma = annual incidence rate per 105.
Lung cancer = annual incidence rate per 103.
accumulative or exponential for epithelial carcinoma but
more age restricted, normal or bimodal in distribution for
cALL and osteosarcoma (as for most paediatric cancers)
(Pochedly, 1987). Note also that the incidence rates of the
two examples of childhood tumours chosen have very
different age distributions. As predicted by epidemiological
(Armitage & Doll, 1954) and mathematical considerations
(Whittemore, 1978; Stein, 1991) and endorsed by recent
molecular biological evidence (Vogelstein et al., 1988), the
adult curve probably reflects the required accumulation of
rare successive mutations in long lived epithelial cells, the risk
of a 'full house' thereby increasing with time. In children, the
distribution suggests a developmentally regulated and
restricted risk period which is different for different cell types.
The incidence rate profile of osteosarcoma is paralleled in
adolescent boys and girls by the post-pubertal spurt of long
bone growth (also the common site of origin of this tumour)
(Meyers, 1987). The simplest explanation of the age distribu-
tions in paediatric cancers is therefore that these reflect
developmentally restricted windows of proliferative stress for
particular tissue specific progenitor cell types. Given that at
least two rate limiting mutations are probably requiredLEUKAEMIC STEM CELLS 419
(Knudson, 1977; Graf, 1988; Haber & Housman, 1991), the
incidence rate at any age in children is likely to reflect the
probability of the final or rate limiting mutation occurring.
In the simplest two-step model, therefore, the earlier or first
mutation could occur at any proceeding time in the same or
an antecedent cell type. In the case of the common (c)
variant of B cell precursor childhood ALL, it was suggested
earlier that the very marked age associated peak of maximum
incidence (2-5 years) (Greaves et al., 1985) reflected the
timing of a penultimate mutation promoted by proliferative
stress associated with infection (Greaves, 1988). This event
was further predicted to occur in a pre-leukaemic clone
initiated in utero.
The concept that paediatric cancers are genetic abnor-
malities of development is not new but there have been few
attempts to rationalise this idea and contrast it with adult
cancers in the context of the biology of tissue specific stem
cells and lineage pathways.
One obvious interpretation of the highly restricted distribu-
tion of the paediatric tumours is that beyond the time-frame
of observed disease, the relevant cell types are effectively not
at risk either because their numbers (as proliferating cells) are
very small or nonexistent and/or specialised micro-
environmental conditions for their growth no longer exist.
This would clearly be compatible with the morphogenic pro-
gramme of non-self-renewing tissue such as muscle or nerve,
compared with most epithelial tissues which must continually
replenish. Embryonic cells which form these structures exist
as a developmental wave of progenitors, e.g. metanephric
blastemal cells in the foetal kidney (Van Heyningen & Hastie,
1992). They need no constitutive stem cell properties but
rather self-renewing capacity which is temporarily expressed
then either exhausted or severely restrained by the developing
tissue itself. The progenitor cells in developmental pathways
in non-renewable tissues may therefore be programmed for
finite or restrained self-renewing properties. Additionally, as
in the lymphoid system, they are associated with a remark-
able degree of apoptosis or programmed cell death (Hin-
chliffe, 1981). It follows from this that unless the genetic
mechanisms underlying neoplasia radically change these pro-
perties, then a corresponding population of malignant
clonogenic cells, as well as their descendant progeny (i.e. in
paediatric solid tumours), would, initially at least, be very
susceptible to varying combinations of drugs and/or radia-
tion for the same reasons as the lymphoid progenitor cells
that give rise to childhood ALL.
Implications for therapy
One clinical implication of the hypothesis discussed here is
that a substantial fraction of adult leukaemias may be intrin-
sically chemo-incurable. Sceptics of this view will point to the
historical perspective on childhood leukaemia and recent,
albeit modest, success in treating adult leukaemia and conc-
lude that more intensification of treatment, better drugs (cf
platinum derivatives in ovarian carcinoma (Hardy et al.,
1991b) or judicious combination of drugs will eventually do
the trick. This optimistic view still prevails but there appears
to be inadequate evidence to sustain it. The alternative posi-
tion is to accept the intractable nature of adult acute
leukaemia and the inherent difficulty of identifying 'conven-
tional' drugs that will discriminate effectively between normal
and leukaemic stem cells and to vigorously pursue different
therapeutic strategies. Those currently used or under develop-
ment include allogeneic bone marrow (stem cell) transplan-
tation as a rescue device for supra-lethal treatment of
patients (Champlin & Gale, 1991). This is in theory the
logical manoeuvre for a multipotential stem cell disease but
has obvious limitations of donor compatibility and inherent
risks of failure or serious side effects. The practicality and
efficacy of this approach may in the future be enhanced by
deriving matched donor stem cells from extensive cord blood
banks (Broxmeyer et al., 1989) and the use of recombinant
growth factors to facilitate speedy haemopoietic reconstitution
(Metcalf, 1985). Other 'biological' approaches to potential
cure include the use of growth factors to 'differentiate-out'
the leukaemic clone (Metcalf, 1985; Fenaux et al., 1992),
anti-sense oligonucleotides (McManaway et al., 1990; Reed et
al., 1990; Calabretta, 1992) that could be targeted to
leukaemia-specific DNA or mRNA sequences, such as the
BCR/ABL junction (Szczylik et al., 1991), and
immunotherapy. The latter approach has a somewhat in-
glorious history in leukaemia and cancer treatment but is
undergoing a renaissance within a more logical framework
with the demonstration of a graft versus leukaemia effect in
transplanted patients (Butturini & Gale, 1989b) and, in par-
ticular, the appreciation that products of deregulated genes,
e.g. IL2 receptor (Waldmann, 1992) and mutated or fused
oncogenes encoding novel gene products, might serve as
targets for antibody or T cell mediated immunological
attack. The latter approach might seem implausible for intra-
cellular proteins such as BCR/ABL or mutated RAS but may
in fact be possible if, as demonstrated in other systems,
intracellular proteins are catabolised and processed to pro-
duce peptides that cycle within the cell and associate with cell
surface MHC molecules (Weiss & Bogen, 1991; Neefjes &
Ploegh, 1992). This view is much encouraged by the demons-
tration that T cells from mice injected with synthetic peptides
can specifically recognise mutated RAS protein (Jung &
Schluesener, 1992) and the BCR/ABL fusion protein (Chen
et al., 1992).
Addendum: exceptions that may prove the rule
Infant acute leukaemias
Infant (<18 months) acute leukaemias occur at a very low
incidence rate but have a particularly poor prognosis (Crist
et al., 1986; Pui et al., 1990). This may in part be explained
by the difficulties of treating such young individuals but
features of the leukaemic cell populations are also likely to
be relevant. The subtypes of acute leukaemia at this age are
different from those of older children with a higher fraction
having myeloid (including megakaryoblastic) features
(Gardembas-Pain et al., 1991). Some of those classified as
ALL may be cryptic erythroleukaemias (Greaves et al., 1983)
and some may have monocytoid plus lymphoid characteris-
tics (Stong et al., 1985). The majority of infant ALL, how-
ever, have a B cell precursor phenotype (but lacking the
CD10 marker of B precursor disease in older children) with
clonal or oligoclonal rearrangements of the IgH gene and a
high frequency (- 75%) of chromosome translocations
involving breaks at 1 1q23 (Raimondi et al., 1989; Gibbons et
al., 1990; Pui et al., 1990). Infant ALL usually presents with
high white cell counts and CNS involvement, both indicative
of a high 'tumour' burden. There is currently no data
available on the clonal origins of these leukaemias. The
prediction which requires testing is that by birth in such
cases, at least one of the necessary two or more genetic
events (including 1 1q23-) have already occurred and that the
disease originates in primitive stem cells that are distinct
from those involved in common ALL.
Non-Hodgkin'sfollicular tymphoma
This tumour of mature B cells is the commonest lymphoid
malignancy in Western countries. It is something of an
enigma since it commonly presents (and persists for many
years) as a low grade benign disease which can be controlled
but not erradicated by treatment and is almost invariably
fatal following eventual progression to high grade diffuse
disease after 10 years or so (Magrath, 1990). The majority of
follicular (centroblastic/centrocytic) lymphomas (>75%)
have a chromosomal translocation which results in dysregula-
tion of the gene BCL-2 by association with the IgH locus
(Bakhshi et al., 1985). In this respect its natural history is not
dissimilar to CML. The BCL-2 gene encodes a 24 kd
mitochondrial membrane protein with the intriguing property420 M.F. GREAVES
of inhibiting the apoptotic programme (Hockenbery et al.,
1990) that is a normal feature of immunological regulation in
germinal centre B cells (Liu et al., 1991). Constitutive expres-
sion of BCL-2 in transgenic mice endows mature B cells with
a long or indefinite life-span, which is interpreted as protec-
tion from apoptosis (McDonnell et al., 1989). It has been
proposed that many chemotherapeutic agents used in cancer
operate by inducing apoptosis (Eastman, 1990). Follicular
lymphoma may then provide one example that fits Pinkel's
assertion that genetic abnormalities determine treatment re-
sponse since high level expression of bcl-2 protein might be
expected to be protective. It will be interesting to see if other
mutated or dysregulated genes in leukaemia, including BCR/
ABL (Daley & Baltimore, 1988) and p53 (Lane, 1992), pro-
vide an escape from apoptosis independently of, or con-
comitant with, their proliferation effects.
Testicular teratomas
These tumours occur in young adults and are remarkably
radio- and chemo-sensitive resulting in high cure rates overall
and including Stage IV patients with extensive metastases
(Peckham, 1981; Einhorn, 1990; Roth & Nichols, 1992).
Several different single agent drugs (e.g. actinomycin D) are
effective in inducing remission although combined drug
regimes are preferred (for advanced stages) recalling the ear-
lier experience with childhood ALL. The cell of origin has
not been identified but is presumed to be an early cell in the
spermatogenesis pathway (Peckham, 1981). It would be a
remarkable coincidence if the efficacy of both radiation and
chemotherapy in this cancer were not associated with the
high sensitivity of normal male germ cells to DNA-damaging
agents (Meistrich & Van Beel, 1990), an unusual feature they
share with lymphocyte progenitor cells.
I am grateful to Professor T.A. Lister, Dr G.J. Morgan and Dr
W.M. Crist for helpful comments, the Leukaemia Research Fund of
Great Britain for support and Ms Barbara Deverson with help in
preparation of the manuscript.
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